LNA043 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Conditions
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Trial Timeline
Nov 16, 2015 → Mar 6, 2018
NCT ID
NCT02491281About LNA043 + Placebo
LNA043 + Placebo is a phase 1 stage product being developed by Novartis for Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02491281. Target conditions include Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04564053 | Phase 1 | Completed |
| NCT02491281 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery